U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.26 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.14 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3583
    -0.0108 (-0.79%)
     
  • USD/JPY

    103.8000
    -0.0160 (-0.02%)
     
  • BTC-USD

    35,850.26
    +849.60 (+2.43%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

Global Bone Morphogenetic Proteins Industry (2020 to 2027) - Market Trends and Drivers - ResearchAndMarkets.com

·2 min read

The "Bone Morphogenetic Proteins - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The publisher brings years of research experience to the 9th edition of this report. The 188-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Bone Morphogenetic Proteins Market to Reach $589.5 Million by 2027

Amid the COVID-19 crisis, the global market for Bone Morphogenetic Proteins estimated at US$508 Million in the year 2020, is projected to reach a revised size of US$589.5 Million by 2027, growing at a CAGR of 2.1% over the period 2020-2027.

Recombinant human bone morphogenetic protein-2 (rhBMP-2), one of the segments analyzed in the report, is projected to record 2.3% CAGR and reach US$398.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Recombinant human bone morphogenetic protein-7 (rhBMP-7) segment is readjusted to a revised 1.8% CAGR for the next 7-year period.

The U. S. Market is Estimated at $149.5 Million, While China is Forecast to Grow at 1.7% CAGR

The Bone Morphogenetic Proteins market in the U. S. is estimated at US$149.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$103.2 Million by the year 2027 trailing a CAGR of 1.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 1.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Competitors identified in this market include, among others:

  • Cellumed Co., Ltd.

  • Medtronic PLC

  • Stryker Corporation

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares

  • Bone Morphogenetic Proteins Competitor Market Share Scenario Worldwide (in %): 2019 & 2025

  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 53

For more information about this report visit https://www.researchandmarkets.com/r/f9ckve

View source version on businesswire.com: https://www.businesswire.com/news/home/20201229005358/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900